Fixing a ‘market failure’: To develop new antibiotics, upend the incentive structure, experts urge

(By Meghana Keshavan for STAT)

LOS ANGELES — Superbugs, and our dwindling arsenal of drugs that can successfully combat them, are a serious public health concern. The private sector, however, is largely unwilling to take on the financial risk of developing new drugs that could help. Those treatments bring little if any profit.  Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.